Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

被引：53

作者：

Wierda, William G. ^{[1
]}

Brown, Jennifer ^{[2
]}

Abramson, Jeremy S. ^{[3
]}

Awan, Farrukh ^{[4
]}

Bilgrami, Syed F. ^{[5
]}

Bociek, Greg ^{[6
]}

Brander, Danielle ^{[7
]}

Chanan-Khan, Asher A. ^{[8
]}

Coutre, Steve E. ^{[9
]}

Davis, Randall S. ^{[10
]}

Eradat, Herbert ^{[11
]}

Fletcher, Christopher D. ^{[12
]}

Gaballa, Sameh ^{[13
]}

Ghobadi, Armin ^{[14
,15
]}

Hamid, Muhammad Saad ^{[16
]}

Hernandez-Ilizaliturri, Francisco ^{[17
]}

Hill, Brian ^{[18
,19
]}

Kaesberg, Paul ^{[20
]}

Kamdar, Manali ^{[21
]}

Kaplan, Lawrence D. ^{[22
]}

Khan, Nadia ^{[23
]}

Kipps, Thomas J. ^{[24
]}

Ma, Shuo ^{[25
]}

Mato, Anthony ^{[26
]}

Mosse, Claudio ^{[27
]}

Schuster, Stephen ^{[28
]}

Siddiqi, Tanya ^{[29
]}

Stephens, Deborah M. ^{[30
]}

Ujjani, Chaitra ^{[31
]}

Wagner-Johnston, Nina ^{[32
]}

Woyach, Jennifer A. ^{[33
]}

Ye, J. Christine ^{[34
]}

Dwyer, Mary A. ^{[35
]}

Sundar, Hema ^{[35
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[4] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[5] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[6] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[7] Duke Canc Inst, Durham, NC USA

[8] Mayo Clin, Canc Ctr, Rochester, MN USA

[9] Stanford Canc Inst, Stanford, CA USA

[10] ONeal Comprehens Canc Ctr UAB, Birmingham, AL USA

[11] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[15] Washington Univ, Sch Med, St Louis, MO USA

[16] Univ Tennessee, Hlth Sci Ctr, St Jude Chidrens Res Hosp, Knoxville, TN 37996 USA

[17] Roswel Pk Comprehens Canc Ctr, Buffalo, NY USA

[18] Univ Hosp Seidman Canc Ctr, Case Comprehensve Canc Ctr, Cleveland, OH USA

[19] Cleveland Clin, Tausslg Canc Inst, Cleveland, OH 44106 USA

[20] UC Davis Comprehens Canc Ctr, Davis, CA USA

[21] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[22] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[23] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[24] UC San Diego Moores Canc Ctr, San Diego, CA USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[26] Mem Sloan Kettering Canc Ctr, Ithaca, NY USA

[27] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] City Hope Natl Med Ctr, Duarte, CA USA

[30] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[31] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[32] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[33] Ohio State Univ, Comprehenslve Canc Ctr, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA

[34] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[35] Natl Comprehens Canc Network, Philadelphia, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 06期

关键词：

MINIMAL RESIDUAL DISEASE; CHLORAMBUCIL PLUS OBINUTUZUMAB; FLOW-CYTOMETRY; OPEN-LABEL; 1ST-LINE TREATMENT; FOLLOW-UP; PHASE-II; IBRUTINIB; VENETOCLAX; CLL;

D O I：

10.6004/jnccn.2022.0031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton???s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-na??ve and relapsed/refractory disease.

引用

页码：622 / 634

页数：13

共 50 条

[21] NCCN Guidelines® Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Kumar, Shaji K.
Callander, Natalie S.
Alsina, Melissa
Atanackovic, Djordje
Biermann, J. Sybil
Castillo, Jorge
Chandler, Jason C.
Costello, Caitlin
Faiman, Matthew
Fung, Henry C.
Godby, Kelly
Hofmeister, Craig
Holmberg, Leona
Holstein, Sarah
Huff, Carol Ann
Kang, Yubin
Kassim, Adetola
Liedtke, Michaela
Malek, Ehsan
Martin, Thomas
Neppalli, Vishala T.
Omel, James
Raje, Noopur
Singhal, Seema
Somlo, George
Stockerl-Goldstein, Keith
Weber, Donna
Yahalom, Joachim
Kumar, Rashmi
Shead, Dorothy A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (01): : 11 - 20
[22] NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Mesa, Ruben A.
Jamieson, Catriona
Bhatia, Ravi
Deininger, Michael W.
Fletcher, Christopher D.
Gerds, Aaron T.
Gojo, Ivana
Gotlib, Jason
Gundabolu, Krishna
Hobbs, Gabriela
McMahon, Brandon
Mohan, Sanjay R.
Oh, Stephen
Padron, Eric
Papadantonakis, Nikolaos
Pancari, Philip
Podoltsev, Nikolai
Rampal, Raajit
Ranheim, Erik
Reddy, Vishnu
Rein, Lindsay A. M.
Scott, Bart
Snyder, David S.
Stein, Brady L.
Talpaz, Moshe
Verstovsek, Srdan
Wadleigh, Martha
Wang, Eunice S.
Bergman, Mary Anne
Gregory, Kristina M.
Sundar, Hema
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (10): : 1193 - 1207
[23] Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines
Motzer, Robert J.
Jonasch, Eric
Agarwal, Neeraj
Alva, Ajjai
Bagshaw, Hilary
Baine, Michael
Beckermann, Kathryn
Carlo, Maria I.
Choueiri, Toni K.
Costello, Brian A.
Derweesh, Ithaar H.
Desai, Arpita
Ged, Yasser
George, Saby
Gore, John L.
Gunn, Andrew
Haas, Naomi
Johnson, Michael
Kapur, Payal
King, Jennifer
Kyriakopoulos, Christos
Lam, Elaine T.
Lara, Primo N.
Lau, Clayton
Lewis, Bryan
Madoff, David C.
Manley, Brandon
Michaelson, M. Dror
Mortazavi, Amir
Ponsky, Lee
Ramalingam, Sundhar
Shuch, Brian
Smith, Zachary L.
Sosman, Jeffrey
Sweis, Randy
Zibelman, Matthew
Schonfeld, Ryan
Stein, MaryElizabeth
Gurski, Lisa A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (01): : 4 - 16
[24] Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Schaeffer, Edward
Srinivas, Sandy
Antonarakis, Emmanuel S.
Armstrong, Andrew J.
Bekelman, Justin E.
Cheng, Heather
D'Amico, Anthony Victor
Davis, Brian J.
Desai, Neil
Dorff, Tanya
Eastham, James A.
Farrington, Thomas A.
Gao, Xin
Horwitz, Eric Mark
Ippolito, Joseph E.
Kuettel, Michael R.
Lang, Joshua M.
Mckay, Rana
McKenney, Jesse
Netto, George
Penson, David F.
Pow-Sang, Julio M.
Reiter, Robert
Richey, Sylvia
Roach, Mack, III
Rosenfeld, Stan
Shabsigh, Ahmad
Spratt, Daniel E.
Teply, Benjamin A.
Tward, Jonathan
Shead, Dorothy A.
Freedman-Cass, Deborah A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 135 - 143
[25] Pancreatic Adenocarcinoma, Version 2.2014 Featured Updates to the NCCN Guidelines
Tempero, Margaret A.
Malafa, Mokenge P.
Behrman, Stephen W.
Benson, Al B., III
Casper, Ephraim S.
Chiorean, E. Gabriela
Chung, Vincent
Cohen, Steven J.
Czito, Brian
Engebretson, Anitra
Feng, Mary
Hawkins, William G.
Herman, Joseph
Hoffman, John P.
Ko, Andrew
Komanduri, MDSrinadh
Koong, Albert
Lowy, Andrew M.
Ma, Wen Wee
Merchant, Nipun B.
Mulvihill, Sean J.
Muscarella, Peter, II
Nakakura, Eric K.
Obando, Jorge
Pitman, Martha B.
Reddy, Sushanth
Sasson, Aaron R.
Thayer, Sarah P.
Weekes, Colin D.
Wolff, Robert A.
Wolpin, Brian M.
Burns, Jennifer L.
Freedman-Cass, Deborah A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (08): : 1083 - 1093
[26] Ovarian Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
Morgan, Robert J., Jr.
Alvarez, Ronald D.
Armstrong, Deborah K.
Burger, Robert A.
Chen, Lee-may
Copeland, Larry
Crispens, Marta Ann
Gershenson, David M.
Gray, Heidi J.
Hakam, Ardeshir
Havrilesky, Laura J.
Johnston, Carolyn
Lele, Shashikant
Martin, Lainie
Matulonis, Ursula A.
O'Malley, David M.
Penson, Richard T.
Powell, Matthew A.
Remmenga, Steven W.
Sabbatini, Paul
Santoso, Joseph T.
Schink, Julian C.
Teng, Nelson
Werner, Theresa L.
Dwyer, Mary A.
Hughes, Miranda
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (10): : 1199 - 1209
[27] Rectal Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines
Benson, Al B., III
Venook, Alan P.
Bekaii-Saab, Tanios
Chan, Emily
Chen, Yi-Jen
Cooper, Harry S.
Engstrom, Paul F.
Enzinger, Peter C.
Fenton, Moon J.
Fuchs, Charles S.
Grem, Jean L.
Grothey, Axel
Hochster, Howard S.
Hunt, Steven
Kamel, Ahmed
Kirilcuk, Natalie
Leong, Lucille A.
Lin, Edward
Messersmith, Wells A.
Mulcahy, Mary F.
Murphy, James D.
Nurkin, Steven
Rohren, Eric
Ryan, David P.
Saltz, Leonard
Sharma, Sunil
Shibata, David
Skibber, John M.
Sofocleous, Constantinos T.
Stoffel, Elena M.
Stotsky-Himelfarb, Eden
Willett, Christopher G.
Gregory, Kristina M.
Freedman-Cass, Deborah
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (06): : 719 - 728
[28] Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
Mohler, James L.
Armstrong, Andrew J.
Bahnson, Robert R.
Boston, Barry
Busby, J. Erik
D'Amico, Anthony Victor
Eastham, James A.
Enke, Charles A.
Farrington, Thomas
Higano, Celestia S.
Horwitz, Eric Mark
Kantoff, Philip W.
Kawachi, Mark H.
Kuettel, Michael
Lee, Richard J.
MacVicar, Gary R.
Malcolm, Arnold W.
Miller, David
Plimack, Elizabeth R.
Pow-Sang, Julio M.
Roach, Mack, III
Rohren, Eric
Rosenfeld, Stan
Srinivas, Sandy
Strope, Seth A.
Tward, Jonathan
Twardowski, Przemyslaw
Walsh, Patrick C.
Ho, Maria
Shead, Dorothy A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (09): : 1081 - 1087
[29] Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
Flaig, Thomas W.
Spiess, Philippe E.
Abern, Michael
Agarwal, Neeraj
Bangs, Rick
Buyyounouski, Mark K.
Chan, Kevin
Chang, Sam S.
Chang, Paul
Friedlander, Terence
Greenberg, Richard E.
Guru, Khurshid A.
Herr, Harry W.
Hoffman-Censits, Jean
Kaimakliotis, Hristos
Kishan, Amar U.
Kundu, Shilajit
Lele, Subodh M.
Mamtani, Ronac
Mian, Omar Y.
Michalski, Jeff
Montgomery, Jeffrey S.
Parikh, Mamta
Patterson, Anthony
Peyton, Charles
Plimack, Elizabeth R.
Preston, Mark A.
Richards, Kyle
Sexton, Wade J.
Siefker-Radtke, Arlene O.
Stewart, Tyler
Sundi, Debasish
Tollefson, Matthew
Tward, Jonathan
Wright, Jonathan L.
Cassara, Carly J.
Gurski, Lisa A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (04): : 216 - 225
[30] Rectal Cancer, Version 6.2020 Featured Updates to the NCCN Guidelines
Benson, Al B., III
Venook, Alan P.
Al-Hawary, Mahmoud M.
Arain, Mustafa A.
Chen, Yi-Jen
Ciombor, Kristen K.
Cohen, Stacey
Cooper, Harry S.
Deming, Dustin
Garrido-Laguna, Ignacio
Grem, Jean L.
Gunn, Andrew
Hoffe, Sarah
Hubbard, Joleen
Hunt, Steven
Kirilcuk, Natalie
Krishnamurthi, Smitha
Messersmith, Wells A.
Meyerhardt, Jeffrey
Miller, Eric D.
Mulcahy, Mary F.
Nurkin, Steven
Overman, Michael J.
Parikh, Aparna
Patel, Hitendra
Pedersen, Katrina
Saltz, Leonard
Schneider, Charles
Shibata, David
Skibber, John M.
Sofocleous, Constantinos T.
Stoffel, Elena M.
Stotsky-Himelfarb, Eden
Willett, Christopher G.
Johnson-Chilla, Alyse
Gurski, Lisa A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 807 - 815

← 1 2 3 4 5 →